Scilex Holding Company (SCLX) Key Metrics

NASDAQ: SCLXValuation, returns, debt and efficiency ratios over 7 years.

SCLX valuation today

Trailing 12 months · as of October 17, 2026
Market cap
$19.9M
Enterprise value
$133.4M
P/E (TTM)
—
Forward P/E
5.6
PEG ratio
—
Price / sales
0.6
10-yr median 3.5
Price / book
28.9
EV / EBITDA
—
Dividend yield
—
Beta
1.79

SCLX key metrics, 2019–2025

Fiscal year ended December 31, 2025 · U.S. dollars

SCLX valuation Price multiples at each fiscal year-end price.

Price / sales+142.9%
2.8
2025 · hover or tap a bar for each year
2021: 26.52022: 8.8 (−66.9%)2023: 3.5 (−59.6%)2024: 1.1 (−67.8%)2025: 2.8 (+142.9%)
20192025
Price / free cash flow+561.0%
22.8
2025 · hover or tap a bar for each year
2024: 3.42025: 22.8 (+561.0%)
20192025
Free cash flow yield−24.6 pts
4.4%
2025 · hover or tap a bar for each year
2021: −3.5%2022: −7.0% (−3.5 pts)2023: −12.7% (−5.7 pts)2024: 29.0% (+41.8 pts)2025: 4.4% (−24.6 pts)
20192025

SCLX valuation history

Fiscal year-endToday7-year median

SCLX returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

SCLX debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

SCLX cash returned to shareholders

DividendsBuybacksFree cash flow

SCLX price vs earnings per share

Share price at year-endEPS (right axis)

SCLX key metrics

2019–2025
Scilex Holding Company key metrics by fiscal year
2025202420232022202120202019
Valuation
Market capitalization$83.8M$64.6M$165.5M$333.5M$830.5M——
Enterprise value$205.4M$99.2M$290.0M$332.7M$980.9M——
Price / sales2.81.13.58.826.5——
Price / book———9.2———
Price / free cash flow22.83.4—————
Price / operating cash flow22.03.3—————
EV / sales6.81.86.28.731.3——
EV / free cash flow55.85.3—————
Earnings yield−428.0%−112.8%−69.1%−7.0%−10.6%——
Free cash flow yield4.4%29.0%−12.7%−7.0%−3.5%——
Dividend yield——6.0%————
Shareholder yield (dividends + buybacks)—0.0%12.1%0.0%0.0%——
Share price at fiscal year-end$7.60$9.29$44.46$86.95$218.81——
Per share
Revenue per share$2.74$8.14$12.56$9.92$8.25$5.84$5.22
Earnings per share−$32.51−$10.47−$30.71−$6.09−$23.30−$11.79−$44.30
Operating cash flow per share$0.35$2.78−$5.56−$5.54−$7.55−$7.80−$14.99
Free cash flow per share$0.33$2.70−$5.65−$6.08−$7.55−$7.81−$15.13
Cash per share$1.00$0.47$1.05$0.57$1.14$1.20—
Book value per share−$18.83−$27.71−$46.46$9.45−$58.98−$35.15—
Tangible book value per share−$25.41−$34.32−$59.88−$4.65−$72.75−$49.04—
Dividends per share——$2.69————
Capex per share$0.01$0.09$0.09$0.54$0.00$0.01$0.14
Debt per share$12.01$5.46$34.51$0.37$40.77$34.39—
Shares outstanding11.0M7.0M3.7M3.8M3.8M4.0M4.0M
Change in shares outstanding+58.7%+86.7%−2.9%+1.0%−5.8%0.0%—
Returns & profitability
Return on assets (ROA)−156.7%−75.0%−121.7%−28.4%−110.9%−58.3%—
Return on tangible assets−122.7%−154.8%−222.7%−72.0%−344.7%−186.5%—
Free cash flow margin12.2%33.1%−45.0%−61.3%−91.5%−133.6%−290.0%
Financial health
Total debt$132.5M$38.0M$128.5M$1.4M$154.7M$138.6M—
Cash & short-term investments$11.0M$3.3M$3.9M$2.2M$4.3M$4.8M—
Net debt$121.6M$34.7M$124.5M−$774,000$150.4M$133.8M—
Debt / equity———0.04———
Debt / assets0.360.411.270.021.991.70—
Current ratio0.080.160.190.660.140.29—
Quick ratio0.070.150.170.630.120.27—
Interest coverage-23.8-42.5-98.7-5.3-3.0-2.7-8.2
Working capital−$445.3M−$218.1M−$203.6M−$15.2M−$146.4M−$56.1M—
Invested capital−$86.2M−$158.0M−$48.4M$35.5M−$73.5M−$7.9M—
Tangible asset value−$284.3M−$238.6M−$222.9M−$17.8M−$276.2M−$197.7M—
Net current asset value−$538.4M−$244.0M−$227.5M−$20.7M−$278.8M−$200.8M—
Graham net-net per share−$50.02−$37.58−$65.08−$8.21−$75.21−$51.58—
Capital allocation
Dividends paid——$10.0M————
Share buybacks (net)—$0$10.0M$0$0——
Dividends + buybacks / free cash flow—0.0%—————
Capex / revenue0.4%1.1%0.7%5.4%0.0%0.1%2.8%
Capex / operating cash flow3.5%3.1%—————
Capex / depreciation0.030.150.080.520.000.010.16
Stock-based compensation / revenue51.2%27.7%31.2%13.9%18.6%22.9%20.6%
R&D / revenue68.5%17.0%27.3%23.8%29.4%42.3%406.6%
SG&A / revenue882.2%210.3%256.0%170.6%161.5%182.4%307.6%
Efficiency
Days sales outstanding251.5196.8218.0170.4159.6203.4—
Days of inventory on hand86.672.765.166.6186.2194.5—
Days payables outstanding1,665.11,023.3575.0215.2622.91,379.2—
Cash conversion cycle (days)-1,327.0-753.7-291.921.7-277.1-981.3—
Receivables turnover1.451.851.672.142.291.79—
Payables turnover0.220.360.631.700.590.26—
Inventory turnover4.215.025.615.481.961.88—
Asset turnover0.130.580.500.460.390.29—
Average receivables$20.8M$30.5M$27.9M$17.8M$13.7M$13.1M—
Average payables$69.4M$46.8M$24.7M$6.4M$6.2M$8.1M—
Average inventory$3.6M$3.3M$2.8M$2.0M$1.9M$1.1M—
Intangibles / total assets19.9%49.4%49.3%62.5%67.1%68.7%—

Computed from SCLX's annual financial statements (latest annual report filed April 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

SCLX valuation and financial ratios

It ended the year with $132.5 million of debt and $11.0 million in cash and short-term investments, net debt of $121.6 million. The share count rose 173.7% from 4.0M to 11.0M over 6 years.

See the SCLX income statement, the SCLX chart for price history, or the SCLX stock overview for the latest quote and news.

SCLX key metrics FAQ

How much debt does Scilex have?

Scilex had total debt of $132.5 million at the end of fiscal 2025.

What is Scilex's free cash flow yield?

Scilex generated $3.7 million of free cash flow in fiscal 2025, a free cash flow yield of 4.4% on its market value at year-end ($83.8 million).

What is Scilex's current ratio?

Scilex's current ratio was 0.08 at the end of fiscal 2025: current assets were 0.08 times current liabilities.

Drug Manufacturers - General key metrics